Key Points
-
The c-Jun NH2-terminal kinases (JNKs) phosphorylate and activate members of the activator protein-1 (AP-1) transcription factor family and other cellular factors implicated in regulating altered gene expression, cellular survival and proliferation in response to cytokines and growth factors, to noxious stimuli and to oncogenic transformation. Because these events are commonly associated with the pathogenesis of a number of human diseases, the potential of JNK inhibitors as therapeutics has attracted considerable interest.
-
Activated immune cells express many genes encoding inflammatory molecules, including cytokines, growth factors, cell surface receptors, cell adhesion molecules and degradative enzymes. Many of these genes are regulated by the JNK pathway, through activation of the transcription factors AP-1 and ATF-2. JNK's represent attractive targets for immunomodulatory drug development.
-
Neurodegenerative diseases, including Alzheimer's, Parkinson's and Huntington's diseases, and stroke, share synaptic loss, neuronal atrophy and death as pathological hallmarks. JNK plays an integral role in neuronal death and this pathway might be operative in various central nervous system disease states.
-
Obesity and type 2 diabetes are the most prevalent and serious of the metabolic diseases. Insulin resistance is closely associated with these syndromes, and is commonly seen in hypertension, and following infection and injury. Mice lacking JNK1 displayed decreased adiposity, significantly improved insulin sensitivity and enhanced insulin receptor signalling in the high-fat and ob/ob models, suggesting JNK as a target for preventing insulin resistance.
-
A substantial body of evidence suggests that JNK activation and c-Jun phosphorylation are required for transformation induced by Ras, an oncogene that is mutationally activated in almost 30% of human cancers. JNK also seems to play a significant role in tumour development, although in certain cases this role might be to promote or inhibit tumour development.
-
The combination of high-throughput screening, kinase-specific libraries and structure-based drug design has facilitated the discovery of selective JNK inhibitors. Determination of the X-ray structure of the members of the mitogen-activated protein kinase family, extracellular signal-regulated kinase, p38 and JNK3 has aided the design of potent yet selective inhibitors of the JNKs. These efforts have led to the patenting of a series of JNK inhibitors.
Abstract
The c-Jun NH2-terminal kinases (JNKs) phosphorylate and activate members of the activator protein-1 (AP-1) transcription factor family and other cellular factors implicated in regulating altered gene expression, cellular survival and proliferation in response to cytokines and growth factors, noxious stimuli and oncogenic transformation. Because these events are commonly associated with the pathogenesis of a number of human diseases, the potential of JNK inhibitors as therapeutics has attracted considerable interest. Here we discuss the evidence supporting the application of JNK inhibitors in inflammatory, vascular, neurodegenerative, metabolic and oncological diseases in humans, and describe the present status of drug discovery targeting JNK.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kyriakis, J. M. & Avruch, J. pp54 microtubule-associated protein 2 kinase. A novel serine/threonine protein kinase regulated by phosphorylation and stimulated by poly-L-lysine. J. Biol. Chem. 265, 17355–17363 (1990).
Hibi, M., Lin, A., Smeal, T., Minden, A. & Karin, M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev. 7, 2135–2148 (1993).
Adler, V., Polotskaya, A., Wagner, F. & Kraft, A. S. Affinity-purified c-Jun amino-terminal protein kinase requires serine/threonine phosphorylation for activity. J. Biol. Chem. 267, 17001–17005 (1992).
Derijard, B. et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76, 1025–1037 (1994).
Kyriakis, J. M. et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369, 156–160 (1994).
Davis, R. J. Signal transduction by the JNK group of MAP kinases. Cell 103, 239–252 (2000). A concise overview of the components of the three mitogen-activated protein kinase signalling pathways and their therapeutic potential.
Gupta, S. et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15, 2760–2770 (1996).
Ventura, J. J., Kennedy, N. J., Lamb, J. A., Flavell, R. A. & Davis, R. J. c-Jun NH2-terminal kinase is essential for the regulation of AP-1 by tumor necrosis factor. Mol. Cell Biol. 23, 2871–2882 (2003).
Tournier, C. et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288, 870–874 (2000).
Lawler, S., Fleming, Y., Goedert, M. & Cohen, P. Synergistic activation of SAPK1/JNK1 by two MAP kinase kinases in vitro. Curr. Biol. 8, 1387–1390 (1998).
Tournier, C. et al. MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev. 15, 1419–1426 (2001).
Enslen, H. & Davis, R. J. Regulation of MAP kinases by docking domains. Biol. Cell 93, 5–14 (2001).
Morrison, D. & Davis, R. J. MAP kinase scaffold proteins in mammals. Annu. Rev. Dev. Cell Biol. (in the press).
Harper, S. J. & LoGrasso, P. Inhibitors of the JNK signaling pathway. Drugs of the Future 26, 957–973 (2001). An excellent review of progress in the discovery of inhibitors of JNK signalling, including recent patent activity.
Maroney, A. C. et al. CEP-1347 (KT7515), a synthetic inhibitor of the mixed lineage kinase family. J. Biol. Chem. 276, 25302–25308 (2001). A detailed description of an inhibitor of JNK signalling that functions upstream of the JNKs.
Manning, A. M. & Mercurio, F. Transcription inhibitors in inflammation. Exp. Opin. Invest. Drugs 6, 555–567 (1997).
Swantek, J. L., Cobb, M. H. & Geppert, T. D. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor-α (TNF-α) translation: glucocorticoids inhibit TNF-α translation by blocking JNK/SAPK. Mol. Cell. Biol. 17, 6274–6282 (1997).
Ishizuka, T. et al. Mast cell tumor necrosis factor α production is regulated by MEK kinases. Proc. Natl Acad. Sci. USA 94, 6358–6363 (1997).
Gum, R., Wang, H., Lengyel, E., Juarez, J. & Boyd, D. Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades. Oncogene 14, 1481–1493 (1997).
Han, Z. et al. Jun-N-terminal kinase in rheumatoid arthritis. J. Pharm. Exp. Therap. 291, 124–130 (1999).
Han, Z. et al. c-Jun N-terminal kinase is required for metalloproteinase (MMP) expression in synoviocytes and regulates bone destruction in adjuvant arthritis. J. Clin. Invest. 108, 73–81 (2001).
Clancy, R. et al. Activation of stress-activated protein kinase in osteoarthritis cartilage: evidence for nitric oxide dependence. Osteoarthritis Cartilage 9, 294–299 (2002).
Bennett, B. L. et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl Acad. Sci. USA 98, 13681–13686 (2001). The first detailed description of the pharmacologic profile of a selective JNK inhibitor.
Han, Z., Chang, L., Yamanishi, Y., Karin, M. & Firestein, G. S. Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis. Arthritis Rheum. 46, 818–823 (2002).
Eynott, P. R., Adcock, I. M. & Chung, P. The effects of selective c-Jun N-terminal kinase inhibition in a sensitized Brown Norway rat model of allergic asthma. Am. J. Respir. Crit. Care Med. 49, S102 (2001).
Sabapathy, K. et al. JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development. Curr. Biol. 9, 116–125 (1999).
Rincon, M. et al. The JNK pathway regulates the in vivo deletion of immature CD4+CD8+ thymocytes. J. Exp. Med. 188, 1817–1830 (1998).
Dong, C. et al. JNK is required for effector T-cell function but not for T-cell activation. Nature 405, 91–94 (2000).
Dong, C. et al. Defective T cell differentiation in the absence of Jnk1. Science 282, 2092–2095 (1998).
Yang, D. D. et al. Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity 9, 575–585 (1998).
Arbour, N. et al. c-Jun NH2-terminal kinase (JNK)1 and JNK2 signaling pathways have divergent roles in CD8+ T cell-mediated antiviral immunity. J. Exp. Med. 195, 801–810 (2002).
Conze, D. et al. c-Jun NH2-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8+ T cell activation. J. Exp. Med. 195, 811–823 (2002).
Su, B. et al. JNK is involved in signal integration during costimulation of T lymphocytes. Cell 77, 727–736 (1994).
Li, W., Whaley, C. D., Mondino, A. & Mueller, D. L. Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+ T cells. Science 271, 1272–1276 (1996).
Rincon, M., Flavell, R. A. & Davis, R. J. Signal transduction by MAP kinases in T lymphocytes. Oncogene 20, 2490–2497 (2001)
Kuan, C. Y. et al. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron 22, 667–676 (1999).
Yang, D. D. et al. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 389, 865–870 (1997).
Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J. & Greenberg, M. E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270, 1326–1331 (1995).
Le-Niculescu, H. et al. Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol. Cell Biol. 19, 751–763 (1999).
Bruckner, S. R. et al. JNK3 contributes to c-Jun activation and apoptosis but not oxidative stress in nerve growth factor-deprived sympathetic neurons. J. Neurochem. 78, 298–303 (2001).
Scheuner, D. et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med. 2, 864–870 (1996).
Morishima, Y. et al. β-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J. Neurosci. 21, 7551–7560 (2001).
Zhu, X. et al. Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease J. Neurochem. 76, 435–441 (2001).
Pei, J -J. et al. Localization of active forms of c-Jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. J. Alzheimer's Dis. 3, 41–48 (2001).
Reynolds, C. H., Utton, M. A., Gibb, G. M., Yates, A. & Anderton, B. H. Stress-activated protein kinase/c-Jun N-terminal kinase phosphorylates Tau protein. J. Neurochem. 68, 1736–1744 (1997).
Shoji, M. et al. JNK activation is associated with intracellular β-amyloid accumulation. Mol. Brain Res. 85, 221–233 (2001).
Reynolds, C. H., Betts, J. C., Blackstock, W. P., Nebreda, A. R. & Anderton, B. H. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and p38, and glycogen synthase kinase-3β. J. Neurochem. 74, 1587–1595 (2001).
Anglade, P. et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12, 25–31 (1997).
Xia, X. G. et al. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc. Natl Acad. Sci. USA 98, 10433–10438 (2001).
Mattson, M. P. Apoptosis in neurodegenerative disorders. Nature Rev. Mol. Cell Biol. 1, 120–129 (2000).
Herdegen, T. et al. Lasting N-terminal phosphorylation of c-Jun and activation of c-Jun N-terminal kinases after neuronal injury. J. Neurosci. 18, 5124–5135 (1998).
Must, A. et al. The disease burden associated with overweight and obesity. JAMA 282, 1523–1529 (1999).
Facchini, F. S., Hua, N. W., Reaven, G. M. & Stoohs, R. A. Hyperinsulinemia: the missing link among oxidative stress and age-related diseases? Free Rad. Biol. Med. 29, 1302–1306 (2000).
Uysal, K. T., Wiesbrock, S. M., Marino, M. W. & Hotamisligil, G. S. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 389, 610–614 (1997).
Withers, D. J. & White, M. F. Insulin action and type 2 diabetes: lessons from knockout mice. Curr. Opin. Endocrinol. Diab. 6, 141–145 (1999).
Withers, D. J. et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391, 900–904 (1998).
Lee, Y. H., Giraud, J., Davis, R. J. & White, M. F. c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J. Biol. Chem. 278, 2896–2902 (2003).
Standaert, M. L. et al. Effects of knockout of the protein kinase C β gene on glucose transport and glucose homeostasis. Endocrinology 140, 4470–4477 (1999).
Hirosumi, J. et al. A central role for JNK in obesity and insulin resistance. Nature 420, 333–337 (2002).
Adjei, A. A. Blocking oncogenic Ras signaling for cancer therapy. J. Natl Cancer Inst. 93, 1062–1074 (2001). A review of different approaches to Ras inhibition, including targeting JNK.
Smeal, T., Binetruy, B., Mercola, D. A., Birrer, M. & Karin, M. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature 354, 494–496 (1991).
Schutte, J., Minna, J. D. & Birrer, M. J. Deregulated expression of human c-Jun transforms primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms rat-1a cells as a single gene. Proc. Natl Acad. Sci. USA 86, 2257–2261 (1989).
Johnson, R., Spiegelman, B., Hanahan, D. & Wisdom, R. Cellular transformation and malignancy induced by ras require c-Jun. Mol. Cell Biol. 16, 4504–4511 (1996).
Eferl, R. et al. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 112, 181–192 (2003).
Schreiber, M. et al. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev. 13, 607–619 (1999).
Ip, Y. T. & Davis, R. J. Signal transduction by the c-Jun N-terminal kinase (JNK) — from inflammation to development. Curr. Opin. Cell Biol. 10, 205–219 (1998).
Potapova, O. et al. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J. Biol. Chem. 272, 14041–14044 (1997).
Potapova, O. et al. c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells. J. Biol. Chem. 275, 24767–24775 (2000).
Behrens, A., Jochum, W., Sibilia, M. & Wagner, E. F. Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation. Oncogene 9, 2657–2663 (2000).
Kennedy, N. J. et al. Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. Genes Dev. 17, 629–637 (2003).
Lei, K. et al. The Bax subfamily of Bcl2-related proteins is essential for apoptotic signal transduction by c-Jun NH2-terminal kinase. Mol. Cell Biol. 22, 4929–4942 (2002).
Yoshida, S. et al. The c-Jun NH2-terminal kinase 3 (JNK3) gene: genomic structure, chromosomal assignment, and loss of expression in brain tumors. J. Hum. Genet. 46, 182–187 (2001).
Nishina, H. et al. Stress-signalling kinase Sek1 protects thymocytes from apoptosis mediated by CD95 and CD3. Nature 385, 350–353 (1997).
Tournier, C. et al. MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev. 15, 1419–1426 (2001).
Teng, D. H. et al. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res. 57, 4177–4182 (1997).
Kim, H. L. et al. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res. 61, 2833–2837 (2001).
Yoshida, B. A. et al. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res. 59, 5483–5487 (1999).
Yamada, S. D. et al. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res. 62, 6717–6723 (2002).
Hess, P., Pihan, G., Sawyers, C. L., Flavell, R. A. & Davis, R. J. Survival signaling mediated by c-Jun NH2-terminal kinase in transformed B lymphoblasts. Nature Genet. 32, 201–205 (2002).
Dumas, J. Protein kinase inhibitors: emerging pharmacophores 1997–2000. Exp. Opin. Ther. Patents 11, 405–429 (2001). An excellent review of the many different kinase inhibitor chemical templates that were identified in the late 1990s.
Gray, N. S. et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533–538 (1998).
Zhang, F., Strand, A., Robbins, D., Cobb, M. H. & Goldsmith, E. J. Atomic structure of the MAP kinase ERK2 at 2.3 Å resolution. Nature 367, 704–711 (1994).
Wilson, K. P. et al. Crystal structure of p38 mitogen-activated protein kinase. J. Biol. Chem. 271, 27696–27700 (1996).
Xie, X. et al. Crystal structure of JNK3: a kinase implicated in neuronal apoptosis. Structure 6, 983–991 (1998). The report of the JNK3 crystal structure provided a key tool for the identification of selective JNK inhibitors.
Bennett, B. L. et al. WO 0112609 (2001).
Bain, J., McLauchlan, H., Elliott, M. & Cohen, P. The specificities of protein kinase inhibitors: an update. Biochem. J. 371, 199–204 (2003).
Kois, A. et al. WO 200246170 (2002).
Press release, dated 10/21/2002; see http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=celg&script=410&layout=9&item_id=346725.A press release announcing the first Phase I clinical trial of a selective JNK inhibitor.
Halazy, S., Church, D., Camps, M. & Gotteland, J. P. WO 0147920 (2001).
Arkinstall, S. et al. WO 0123379 (2001).
Arkinstall, S. et al. WO 0123378 (2001).
Arkinstall, S. et al. WO 0123382 (2001).
Salituro, F. G. et al. WO 0064872 (2000).
Green, J. et al. WO 0112621 (2001).
Ohkawa, S., Naruo, K., Miwatashi, S., Kimura, H. & Kawamoto, T. WO 2002062792 (2002).
Corbett, W. L. & Luk, K. -C. & Mahaney, P. E. WO 0035909 (2000).
Luk, K. -C., Mahaney, P. E. & Mischke, S. G. WO 0035906 (2000).
Luk, K. -C. & Michoud, C. WO 0035921 (2000).
Radcliffe, A. J. et al. WO 2003024967 (2003).
Oinuma, H., Ohi, N., Sato, N. & Seshimo, H. WO 2002083648 (2002).
Graczyk, P. et al. WO 2002081475 (2002).
Lograsso, P. et al. WO 200191749 (2001).
Weston, C. R. & Davis, R. J. The JNK signal transduction pathway. Curr. Opin. Genet. Dev. 12, 14–21 (2002).
Author information
Authors and Affiliations
Corresponding author
Glossary
- AP-1 TRANSCRIPTION FACTOR
-
The transcription factor AP-1 is composed of homo- or hetero-dimers of proteins that belong to the FOS and JUN families. JUN proteins can homo-dimerize, but FOS proteins can only form stable dimers with JUN. AP-1 dimers can be phosphorylated by JNK and other MAP kinases and hence develop an enhanced DNA-binding capacity and transcriptional activity.
- IC50
-
The concentration of drug at which activity of a particular assay is inhibited by 50%. This is a typically used value to describe the relative potency of a drug agent.
- NEUROFIBRILLARY TANGLES
-
Intracellular aggregates of paired helical filaments composed primarily of hyper-phosphorylated Tau proteins. Tau is a microtubule-associated protein found within neurons and normally restricted to axons. Hyper-phosphorylated Tau forms tangled masses that consume the neuronal cell body, presumably leading to neuronal dysfunction and ultimately cell death.
Rights and permissions
About this article
Cite this article
Manning, A., Davis, R. Targeting JNK for therapeutic benefit: from junk to gold?. Nat Rev Drug Discov 2, 554–565 (2003). https://doi.org/10.1038/nrd1132
Issue Date:
DOI: https://doi.org/10.1038/nrd1132
This article is cited by
-
Anti-hyperalgesic effects of photobiomodulation therapy (904 nm) on streptozotocin-induced diabetic neuropathy imply MAPK pathway and calcium dynamics modulation
Scientific Reports (2022)
-
Neuronal chemokine-like-factor 1 (CKLF1) up-regulation promotes M1 polarization of microglia in rat brain after stroke
Acta Pharmacologica Sinica (2022)
-
Glycine, the smallest amino acid, confers neuroprotection against d-galactose-induced neurodegeneration and memory impairment by regulating c-Jun N-terminal kinase in the mouse brain
Journal of Neuroinflammation (2020)
-
The role of stress kinases in metabolic disease
Nature Reviews Endocrinology (2020)
-
Fe3O4@SiO2-PTMS-Guanidine-SA nanoparticles as an effective and reusable catalyst for the synthesis of N-substituted pyrroles
Journal of the Iranian Chemical Society (2020)